Abstract
Background Alzheimer’s disease (AD) is often preceded by stages of cognitive impairment, namely subjective cognitive decline (SCD) and mild cognitive impairment (MCI). While cerebrospinal fluid (CSF) biomarkers are established predictors of AD, other non-invasive candidate predictors include personality traits, anxiety, and depression, among others. There predictors offer non-invasive assessment and exhibit changes during AD development and preclinical stages.
Methods In a cross-sectional design, we comparatively evaluated the predictive value of personality traits (Big Five), geriatric anxiety and depression scores, resting-state functional magnetic resonance imaging activity of the default mode network, apoliprotein E (ApoE) genotype, and CSF biomarkers (tTau, pTau181, Aβ42/40 ratio) in a multi-class support vector machine classification. Participants included 189 healthy controls (HC), 338 individuals with SCD, 132 with amnestic MCI, and 74 with mild AD from the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE).
Results Mean predictive accuracy across all participant groups was highest when utilizing a combination of personality, depression, and anxiety scores. HC were best predicted by a feature set comprised of depression and anxiety scores and participants with AD were best predicted by a feature set containing CSF biomarkers. Classification of participants with SCD or aMCI was near chance level for all assessed feature sets.
Conclusion Our results demonstrate predictive value of personality trait and state scores for AD. Importantly, CSF biomarkers, personality, depression, anxiety, and ApoE genotype show complementary value for classification of AD and its at-risk stages.
Key Points
– Multi-class support vector machine classification was used to compare the predictive value of well-established and non-invasive, easy-to-assess candidate variables for classifying participants with healthy cognition, subjective cognitive decline, amnestic mild cognitive impairment, and mild Alzheimer’s disease.
– Personality traits, geriatric anxiety and depression scores, resting-state functional magnetic resonance imaging activity of the default mode network, ApoE genotype, and CSF biomarkers were comparatively evaluated.
– A combination of personality, anxiety, and depression scores provided the highest predictive accuracy, comparable to CSF biomarkers, indicating complementary value.
– Established and candidate predictors had limited success in classifying SCD and aMCI, underscoring the heterogeneity of these cognitive states and emphasizing the need for standardizing terminology and diagnostic criteria.
Competing Interest Statement
F. Jessen received fees for consultations and presentations between 2019 and 2022 from AC Immune, Biogen, Danone/Nutricia, Eisai, GE Healthcare, Grifols, Janssen, Lilly, MSD, Novo Nordisk, and Roche. E. Düzel is cofounder of neotiv GmbH. The remaining authors report no disclosures relevant to the manuscript.
Clinical Protocols
https://drks.de/search/de/trial/DRKS00007966
Funding Statement
The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen [DZNE]), reference number BN012.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Institutional Review Boards of all participating study centers of the DZNE. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn (registration number 117/13).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses k.waschkies{at}stud.uni-goettingen.de, Joram.Soch{at}dzne.de, margarita.darna{at}lin-magdeburg.de, Anni.Richter{at}lin-magdeburg.de, slawek.altenstein{at}charite.de, Aline.Beyle{at}dzne.de, Frederic.Brosseron{at}dzne.de, andrea.lohse{at}charite.de, Michaela.Butryn{at}dzne.de, laura.dobisch{at}dzne.de, michael.ewers{at}med.uni-muenchen.de, Klaus.Fliessbach{at}ukbonn.de, tatjana.gabelin{at}charite.de, Wenzel.Glanz{at}dzne.de, doreen.goerss{at}dzne.de, daria.gref{at}charite.de, Daniel.Janowitz{at}med.uni-muenchen.de, Ingo.Kilimann{at}dzne.de, friederike.buchholz{at}charite.de, Matthias.Munk{at}med.uni-tuebingen.de, boris.rauchmann{at}med.uni-muenchen.de, ayda.rostamzadeh{at}uk-koeln.de, nina.roy{at}dzne.de, eike.spruth{at}charite.de, pdechen{at}gwdg.de, Michael.Ewers{at}med.uni-muenchen.de, Michael.Heneka{at}dzne.de, stefan.hetzer{at}charite.de, alfredo.ramirez-zuniga{at}uk-koeln.de, klaus.scheffler{at}med.uni-tuebingen.de, katharina.buerger{at}med.uni-muenchen.de, Christoph.Laske{at}med.uni-tuebingen.de, Robert.Perneczky{at}med.uni-muenchen.de, oliver.peters{at}charite.de, josef.priller{at}charite.de, anja.schneider{at}dzne.de, annika.spottke{at}dzne.de, stefan.teipel{at}med.uni-rostock.de, emrah.duezel{at}dzne.de, frank.jessen{at}uk-koeln.de, jens.wiltfang{at}med.uni-goettingen.de, Bjoern-Hendrik.Schott{at}dzne.de, kizilirmak{at}uni-hildesheim.de
Data availability statement All scripts (https://github.com/jmkizilirmak/DELCODE162) and the machine learning toolbox for Matlab (https://github.com/JoramSoch/ML4ML) are available online. Data, study protocol, and biomaterials can be shared with collaborators based on individual data and biomaterial transfer agreements with the DZNE.
Funding statement The study was funded by the German Center for Neurodegenerative Diseases (DZNE), reference number BN012.
Conflict of interest disclosure F. Jessen has received consulting fees from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen, and Lundbeck. E. Düzel is co-founder of neotiv GmbH. The remaining authors report no disclosures relevant to the manuscript.
Ethics approval statement The study protocol was approved by the Institutional Review Boards of all participating study centers of the DZNE. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn (registration number 117/13).
Patient consent statement All participants gave written informed consent.
Permission to reproduce material from other sources Not applicable.
Clinical trial registration The DELCODE study has been registered as a clinical trial with the German Clinical Trials Register under the study acronym "DELCODE", ID DRKS00007966.
Title We have revised the title of the manuscript to better represent the study and its findings. Introduction We have revised the introduction to highlight the distinction between depression and anxiety measures as capturing transient states and trait measures encompassing the Big Five personality traits. The paragraphs introducing the background and significance of anxiety and depression have been revised for clarity and depth, and the wording of the hypotheses for clarity. Materials and Methods We now explicitly point out that our study employs a cross-sectional design and does not make predictions about transitions and future diagnoses (sections 2.1 and 2.8). A more comprehensive description of the participant groups and additional detail of the recruitment process have been added (section 2.1). We have included an additional feature set consisting of GDS and GAI-SF scores. However, to maintain our focus on personality traits and avoid excessive multiple testing, we have decided not to incorporate additional feature sets solely consisting of GDS and GAI-SF scores. We have provided a more detailed description of the procedure for obtaining non-imaging markers (sections 2.4 to 2.8). The description of mPerAF as a resting-state measure and the definition of the decoding accuracy have been improved (sections 2.3 and 2.8). Results Numbering and ordering of the feature sets in the figures and tables is now consistent. The reporting of prediction accuracies has been enhanced by including a third decimal place in the results. A figure showing the four best-performing feature sets has been added (Figure 4). Discussion We expanded the discussion of the overall poor prediction accuracies for the SCD and aMCI participant groups (section 4.3) and have included a discussion of anosognosia in sections 4.3 and 4.4. We have highlighted the potential influence of caregivers assisting participants with AD in completing the questionnaires.
Data Availability
All scripts used to perform the analyses are available under https://github.com/jmkizilirmak/DELCODE162. Data can be made available to cooperation partners of the DZNE after setting up appropriate data sharing contracts.
